Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-05-21
2010-06-01
Peng, Bo (Department: 1648)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388800, C530S388300
Reexamination Certificate
active
07728110
ABSTRACT:
The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to human SARS-CoV S protein, and that function to neutralize SARS-CoV. The invention also relates to antibodies that are bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-SARS-CoV S protein antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-SARS-CoV S protein antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.
REFERENCES:
patent: 5849992 (1998-12-01), Meade et al.
patent: 5959177 (1999-09-01), Hein et al.
patent: 2005/0069869 (2005-03-01), Ambrosino et al.
patent: 2005/0249739 (2005-11-01), Marasco et al.
patent: WO2005/018538 (2005-03-01), None
patent: WO/2005/054469 (2005-06-01), None
patent: WO2005/056585 (2005-06-01), None
patent: WO2005/060520 (2005-07-01), None
patent: WO2006/051091 (2006-05-01), None
Nara PL, Lin G.“HIV-1: the confounding variables of virus neutralization.”Curr Drug Targets Infect Disord. Jun. 2005;5(2):157-70.
Green LL. “Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies.” J Immunol Methods. Dec. 10, 1999;231(1-2):11-23.
Kashmiri SV, et al. “SDR grafting-a new approach to antibody humanization” Methods. May 2005;36(1):25-34.
Rudikoff S, “Single amino acid substitution altering antigen-binding specificity.” Proc Natl Acad Sci U S A. Mar. 1982;79(6):1979-83.
Ko and Koprowski, Plant biopharming of monoclonal antibodies, Virus Res. 111:93-100 (2005).
Lai et al., Characterization of neutralizing monoclonal; antibodies recognizing a 15-residues epitope on the spike protein HR2 region of severe acute respiratory syndrome coronavirus (SARS-CoV), J. Biol. Sci. 12:711-727 (2005).
Qiu et al., Antibody responses to individual proteins of SARS coronavirus and their neutralization activities, Microbes and Inf. 7:882-889 (2005).
Sola et al., Transgenic mice secreting coronavirus neutralizing antibodies into the milk, J. Virol. 3762-3772 (1998).
Ter Meulen et al., Human monoclonal antibody as prophylaxis for SARA coronavirus infection in ferrets, The Lancet 363:2139-2141 (2004).
Tripp et al., Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): Identification of neutralizing and antibodies reactive to S, N, M and E viral proteins, J. Virol. Meth. 128:21-28 (2005).
Zhang et al., Human monoclonal antibodies to the S glycoprotein and related proteins as potential therapeutics for SARS, Curr. Op. Mol. Ther. 7(2):151-156.
Babcook et al., 1996, A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities, Proc. Natl. Acad. Sci. USA 93:7843-7848.
Baker, 2004, Coronaviruses: from common colds to severe acute respiratory syndrome, Pediatr. Infect. Dis. J. 23:1049-1050.
Berry et al., 2004, Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus, J. Virol. Meth. 120:87-96.
Bisht et al., 2004, Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice, Proc. Natl. Acad. Sci. USA 101:6641-6646.
Buchholz et al., 2004, Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity, Proc. Natl. Acad. Sci. USA 101:9804-9809.
Chan et al., 2006, SARS: clinical presentation, transmission, pathogenesis and treatment options, Clin. Sci. 110:193-204.
Cheng et al., 2005, Use of convalescent plasma therapy in SARS patients in Hong Kong, Eur. J. Clin. Microbiol. 24:44-46.
Coughlin et al., 2007, Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse, Virol. 361(1):93-102.
Davis et al., 2004, Production of human antibodies from transgenic mice, Meth. Mol. Biol. 248:191-200.
Gallo et al., 2000, The human immunoglobulin loci introduced into mice: V (D) and J gene segment usage similar to that of adult humans, Eur. J. Immunol. 30:534-540.
Greenough et al., 2005, Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice, J. Infect. Dis. 191:507-514.
Griffiths et al., Human anti-self antibodies with high specificity from phage display libraries, EMBO J. 12:725-734.
Griffiths et al., 1994, Isolation of high affinity human antibodies directly from large synthetic repertoires EMBO J. 13:3245-3260.
Hanauer and Present, 2003, The state of the art in the management of inflammatory bowel disease, Rev. Gastroenterol. Disord. 3:81-92.
He et al., 2004, Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine, Biochem. Biophys. Res. Commun. 324:773-781.
He et al., 2005, Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies, J. Immunol. 174:4908-4915.
He et al., 2005, Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines, Virology 334:74-82.
Hofmann et al., 2004, S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients, J. Virol. 78:6134-6142.
Huang et al., 2002, Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma, Am. J. Pathol. 161:125-134.
Li et al., 2003, Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus, Nature 426:450-454.
Li et al., 2005, Structure of SARS coronavirus spike receptor-binding domain complexed with receptor, Science 309:1864-1868.
Li et al., 2005, Bats are natural reservoirs of SARS-like coronaviruses, Science 310:676-679.
Lonberg, 2005, Human antibodies from transgenic animals, Nat. Biotech. 23:1117-1125.
Marks et al., 1991, Eur. J. Immunol. 21:980-991.
Nissim et al., 1994, Antibody fragments from a ‘single pot’ phage display library as immunochemical reagents, 13(3):692-698.
Piedimonte et al., 2000, A humanized monoclonal antibody against respiratory syncytial virus (palivizumab) inhibits RSV-induced neurogenic-mediated inflammation in rat airways, Pediatr. Res. 47:351-356.
Rathanaswami et al., 2005, Demonstration of an in vivo generated sub-picomolar affinity fully human monoclonal antibody to interleukin-8, Biochem. Biophys. Res. Commun. 334:1004-1013.
Ross et al., 2003, The Her-2
eu gene and protein in breast cancer 2003: biomarker and target of therapy, Oncologist 8:307-325.
Subbarao et al., 2004, Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice, J. Virol. 78:3572-3577.
Sui et al., 2005, Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants, J. Virol. 79:5900-5906.
Sui, 2004, Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association, Proc. Natl. Acad. Sci. USA 101(8):2536-2541.
Ter Meulen et al., 2006, Human monoclonal antibody combination against SARS coronaviru
Babcook John S.
Coughlin Melissa
Prabhakar Bellur S.
Amgen Inc.
Gunnison Jane T.
Murphey Ryan D.
Peng Bo
Ropes & Gray LLP
LandOfFree
Antibodies to SARS coronavirus does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies to SARS coronavirus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies to SARS coronavirus will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4246780